Muscular Dystrophy

References

Anderson JL, Head SI, et al. Brain function in Duchenne muscular dystrophy. Brain. 2002;125:4–13.

Aparicio LF, Jurkovic M, et al. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J Pediatr Orthop. 2002;22:179–81.

Archer JD, Vargas CC, et al. Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 2006 Apr;20(6):738–40.

Balaban B, Matthews DJ. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: Long-term effect. Am J Phys Med Rehabil. 2005 Nov;84(11):843–50.

Balagopal P, Olney R, et al. Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E530–E539.

Barton ER, Morris L, et al. Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve. 2005 Dec;32(6):751–60.

Beenakker EA, Fock JM, et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: A randomized controlled trial. Arch Neurol. 2005 Jan;62(1):128–32.

Bianchi ML, Mazzanti A, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int. 2003 Sep;14(9):761–7.

Billard C, Gillet P, et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neural. 1998;40:12–20.

Buetler TM, Renard M, et al. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr. 2002 Apr;75(4):749–53.

Chaubourt E, Fossier P, et al. Nitric oxide and 1-arginine cause an accumulation of utrophin at the sarcolemma: A possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis. 1999 Dec;6(6):499–507.

Chaubourt E, Voisin V, et al. Muscular nitric oxide synthase (muNOS) and utrophin. J Physiol Paris. 2002 Jan-Mar;96(1-2):43–52.

Conte Camerino D, Tricarico D, et al. Taurine and skeletal muscle disorders. Neurochem Res. 2004 Jan;29(1):135–42.

Cooper R, Morre DJ, et al. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med. 2005 Jun;11(3):521–8.

De Luca A, Pierno S, et al. Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine. Br J Pharmacol. 2001 Mar;132(5):1047–54.

De Luca A, Pierno S, et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther. 2003 Jan;304(1):453–63.

Dorchies OM, Wagner S, et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006 Feb;290(2):C616–C625.

Dubowitz V. Muscle disorders in childhood. 2nd ed. London: WB Saunders Company Ltd; 1995.

Escolar DM, Buyse G, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005 Jul;58(1):151–5.

Felber S, Skladal D, et al. Oral creatine supplementation in Duchenne muscular dystrophy: A clinical and 31P magnetic resonance spectroscopy study. Neurol Res. 2000 Mar;22(2):145–50.

Ferrucci L, Cherubini A, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2006 Feb;91(2):439–46.

Folkers K, Simonsen R. Two successful double blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenie atrophies. Biochim Biophys Acta. 1995;1271:281–6.

Griggs RC, Pandya S, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989 Feb;39(2 Pt 1):219–22.

Guglieri M, Magri F, et al. Molecular etiopathogenesis of limb girdle muscular and congenital muscular dystrophies: Boundaries and contiguities. Clin Chim Acta. 2005 Nov;361(1-2):54–79.

Hankard RG, Hammond D, et al. Oral glutamine slows down whole body protein breakdown in Duchenne muscular dystrophy. Pediatr Res. 1998 Feb;43(2):222–6.

Hankard R, Mauras N, et al. Is glutamine a ‘conditionally essential’ amino acid in Duchenne muscular dystrophy? Clin Nutr. 1999 Dec;18(6):365–9.

Kasai T, Abeyama K, et al. Decreased total nitric oxide production in patients with duchenne muscular dystrophy. J Biomed Sci. 2004 Jul-Aug;11(4):534–7.

Katiyar SK. Skin photoprotection by green tea: Antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord. 2003 Sep;3(3):234–42.

Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol. 2001 Jun;18(6):1307–13.

La Guardia M, Giammanco S, et al. Omega 3 fatty acids: Biological activity and effects on human health. Panminerva Med. 2005 Dec;47(4):245–57.

Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000;20:711–4.

Leighton S. Nutrition for boys with Duchenne muscular dystrophy. (Review). Nutrition & Dietetics: J Dieticians Asso of Australia. 2003 March;60(1):11–6.

Levis S, Gomez A, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab. 2005 Mar;90(3):1557–62.

Louis M, Lebacq J, et al. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve. 2003 May;27(5):604–10.

Manzur AY, Kuntzer T, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725.

Marques MJ, Luz MA, et al. Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci Lett. 2005 Jul 15;382(3):342–5.

Morley N, Clifford T, et al. The green tea polyphenol (-)-epigallocatechin gallate and green tea can protect human cellular DNA from ultraviolet and visible radiation-induced damage. Photodermatol Photoimmunol Photomed. 2005 Feb;21(1):15–22.

Nieto-Ceron S, del Campo LF, et al. Muscular dystrophy by merosin deficiency decreases acetylcholinesterase activity in thymus of Lama2dy mice. J Neurochem. 2005 Nov;95(4):1035–46.

Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs. 2004;64(7):725–50.

Passaquin AC, Renard M, et al. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul Disord. 2002 Feb;12(2):174–82.

Payne ET, Yasuda N. Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve. 2006 Jan;33(1):66–77.

Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001 Jun;53(2):161–76.

Pierno S, De Luca A, et al. Chronic administration of taurine to aged rats improves the electrical and contractile properties of skeletal muscle fibers. J Pharmacol Exp Ther. 1998 Sep;286(3):1183–90.

Porter JD, Khanna S, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002 Feb 1;11(3):263–72.

Ruegg UT, Nicolas-Metral V, et al. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord. 2002 Oct;12 Suppl 1:S155–S161.

Siciliano G, Mancuso M, et al. Coenzyme Q10, exercise lactate and CTG trinucleotide expansion in myotonic dystrophy. Brain Res Bull. 2001 Oct-Nov 1;56(3-4):405–10.

Tarnopolsky MA, Mahoney DJ, et al. Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology. 2004 May 25;62(10):1771–7.

Tedeschi D, Lombardi V, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: New diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21(5 Suppl):S979–S980.

Tidball JG, Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: Targeting downstream events. Pediatr Res. 2004 Dec;56(6):831–41.

Tidball JG, Wehling-Henricks M. Damage and inflammation in muscular dystrophy: Potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol. 2005 Nov;17(6):707–13.

Walter MC, Lochmuller H, et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology. 2000 May 9;54(9):1848–50.

Walter MC, Reilich P, et al. Creatine monohydrate in myotonic dystrophy: A double-blind, placebo-controlled clinical study. J Neurol. 2002 Dec;249(12):1717–22.

Webb AR, Kline L, et al. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373–8.

Yilmaz O, Karaduman A, et al. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Eur J Neurol. 2004 Aug;11(8):541–4.

Zamaria N. Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev. 2004 May-Jun;44(3):273–82.

Zaveri NT. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. Life Sci. 2006 Mar 27;78(18):2073–80.